UBS Group
VVOS icon

UBS Group’s Vivos Therapeutics VVOS Stock Holding History

UBS Group’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.8K Buy
39,154
+28,108
+254% +$22K ﹤0.01% 8230
2026
Q1 		$13K Sell
11,046
-1,631
-13% -$2.61K ﹤0.01% 8230
2025
Q4 		$25.7K Buy
12,677
+12,575
+12,328% +$31.1K ﹤0.01% 7615
2025
Q3 		$316 Sell
102
-142,699
-100% -$647K ﹤0.01% 9738
2025
Q2 		$451K Buy
142,801
+140,922
+7,500% +$356K ﹤0.01% 6096
2025
Q1 		$5.36K Buy
1,879
+1,490
+383% +$5.85K ﹤0.01% 9007
2024
Q4 		$1.67K Buy
389
+311
+399% +$1.04K ﹤0.01% 9185
2024
Q3 		$204 Buy
+78
New +$204 ﹤0.01% 9073
2023
Q4 		– Sell
-370
Closed -$1.78K – 9936
2023
Q3 		$1.78K Buy
+370
New +$2.79K ﹤0.01% 7834
2023
Q1 		– Sell
-752
Closed -$7.53K – 10449
2022
Q4 		$7.53K Buy
752
+365
+94% +$5.34K ﹤0.01% 8888
2022
Q3 		$6K Buy
387
+298
+335% +$9.08K ﹤0.01% 9072
2022
Q2 		$3K Buy
+89
New +$3.7K ﹤0.01% 9377
2022
Q1 		– Sell
-683
Closed -$38K – 10963
2021
Q4 		$38K Buy
683
+567
+489% +$45.6K ﹤0.01% 7174
2021
Q3 		$12K Buy
116
+22
+23% +$2.31K ﹤0.01% 7792
2021
Q2 		$12K Buy
94
+9
+11% +$1.47K ﹤0.01% 7905
2021
Q1 		$14K Buy
+85
New +$15.2K ﹤0.01% 7683

Other funds holding VVOS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.7B AUM 25.67% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
CWM
Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group's VVOS Position: Q2 2026 in Review

UBS Group increased its Vivos Therapeutics (VVOS) stake by 254% in Q2 2026, buying an estimated $22K and bringing the position to 39,154 shares worth $17.8K. The position accounts for ﹤0.01% of the portfolio, ranked #8230.

UBS Group first reported a position in VVOS in Q1 2021 and has held it in 16 quarters since. The position peaked at $451K in Q2 2025. 23 funds tracked by Wall St. Rank hold VVOS as of Q2 2026.

  • UBS Group held 39,154 shares of Vivos Therapeutics worth $17.8K as of Q2 2026.
  • UBS Group bought 28,108 Vivos Therapeutics shares in Q2 2026, an estimated $22K.
  • Vivos Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8230 holding.
  • UBS Group first reported a position in Vivos Therapeutics in Q1 2021 and has held it in 16 quarters since.
  • UBS Group's Vivos Therapeutics position peaked at $451K in Q2 2025.
  • 23 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.